Cargando…
From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176695/ https://www.ncbi.nlm.nih.gov/pubmed/30319951 http://dx.doi.org/10.4103/picr.PICR_102_18 |
| _version_ | 1783361743297183744 |
|---|---|
| author | Raj, Gerard Marshall |
| author_facet | Raj, Gerard Marshall |
| author_sort | Raj, Gerard Marshall |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6176695 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61766952018-10-12 From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? Raj, Gerard Marshall Perspect Clin Res Letter to Editor Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6176695/ /pubmed/30319951 http://dx.doi.org/10.4103/picr.PICR_102_18 Text en Copyright: © 2018 Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Letter to Editor Raj, Gerard Marshall From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title | From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title_full | From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title_fullStr | From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title_full_unstemmed | From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title_short | From “Glivec(®)” to “Prevnar 13(®)”: How strong is the Indian drug patenting system? |
| title_sort | from “glivec(®)” to “prevnar 13(®)”: how strong is the indian drug patenting system? |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176695/ https://www.ncbi.nlm.nih.gov/pubmed/30319951 http://dx.doi.org/10.4103/picr.PICR_102_18 |
| work_keys_str_mv | AT rajgerardmarshall fromglivectoprevnar13howstrongistheindiandrugpatentingsystem |